HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $23 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.2%

Neg 0% Neu 91.2% Pos 0%

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Candel Therapeutics (NASDAQ:CADL) with a Buy and maintains $23 price target.